INTRODUCTION Nodal categories for malignant pleural mesothelioma are derived from the lung cancer staging system and have not been adequately validated. The International Association for the Study of Lung Cancer developed a multinational database to generate evidence-based recommendations to inform the eighth edition of the TNM classification of malignant pleural mesothelioma. METHODS Data from 29 centers were entered prospectively (n = 1566) or by transfer of retrospective data (n = 1953). Survival according to the seventh edition N categories was evaluated using Kaplan-Meier survival curves and Cox proportional hazards regression analysis. Survival was measured from the date of diagnosis. RESULTS There were 2432 analyzable cases: 1603 h...
International audiencePURPOSE: To analyze all nonlymphatic metastatic components (T4 and M1) of the ...
Abstract Background: Analysis of the International Association for the Study of Lung Cancer (IASLC) ...
AbstractObjectives: Progress in the therapy of malignant pleural mesothelioma is limited by the lack...
INTRODUCTION Nodal categories for malignant pleural mesothelioma are derived from the lung cancer st...
Introduction Nodal categories for malignant pleural mesothelioma are derived from the lung cancer st...
INTRODUCTION The M component and TNM stage groupings for malignant pleural mesothelioma (MPM) have b...
Introduction The M component and TNM stage groupings for malignant pleural mesothelioma (MPM) have b...
Introduction: The current T component for malignant pleural mesothelioma (MPM) has been predominantl...
INTRODUCTION The current T component for malignant pleural mesothelioma (MPM) has been predominantly...
BackgroundThe current staging system for malignant pleural mesothelioma (MPM) is controversial. To p...
For nearly 40 years, there was no generally accepted staging system for malignant pleural mesothelio...
For nearly 40 years, there was no generally accepted staging system for malignant pleural mesothelio...
ObjectivesThe propensity of malignant pleural mesothelioma to metastasize to N1 or N2 nodes and thei...
BACKGROUND: The current staging system for malignant pleural mesothelioma (MPM) is controversial. To...
Background: The current staging system for malignant pleural mesothelioma (MPM) is controversial. To...
International audiencePURPOSE: To analyze all nonlymphatic metastatic components (T4 and M1) of the ...
Abstract Background: Analysis of the International Association for the Study of Lung Cancer (IASLC) ...
AbstractObjectives: Progress in the therapy of malignant pleural mesothelioma is limited by the lack...
INTRODUCTION Nodal categories for malignant pleural mesothelioma are derived from the lung cancer st...
Introduction Nodal categories for malignant pleural mesothelioma are derived from the lung cancer st...
INTRODUCTION The M component and TNM stage groupings for malignant pleural mesothelioma (MPM) have b...
Introduction The M component and TNM stage groupings for malignant pleural mesothelioma (MPM) have b...
Introduction: The current T component for malignant pleural mesothelioma (MPM) has been predominantl...
INTRODUCTION The current T component for malignant pleural mesothelioma (MPM) has been predominantly...
BackgroundThe current staging system for malignant pleural mesothelioma (MPM) is controversial. To p...
For nearly 40 years, there was no generally accepted staging system for malignant pleural mesothelio...
For nearly 40 years, there was no generally accepted staging system for malignant pleural mesothelio...
ObjectivesThe propensity of malignant pleural mesothelioma to metastasize to N1 or N2 nodes and thei...
BACKGROUND: The current staging system for malignant pleural mesothelioma (MPM) is controversial. To...
Background: The current staging system for malignant pleural mesothelioma (MPM) is controversial. To...
International audiencePURPOSE: To analyze all nonlymphatic metastatic components (T4 and M1) of the ...
Abstract Background: Analysis of the International Association for the Study of Lung Cancer (IASLC) ...
AbstractObjectives: Progress in the therapy of malignant pleural mesothelioma is limited by the lack...